Deerfield Beach, FL -- (SBWIRE) -- 09/20/2016 -- Latest industry research report on Cancer Biomarkers help to diagnose or identify the patients at a risk of developing cancer, by measuring their level in blood or body fluids. These are the endogenous proteins or metabolites secreted by tumor itself or by body in response to the presence of cancer. Biomarkers are also indicative of disease progression and response to cancer therapies. Cancer is one of the deadliest diseases associated with high mortality rates across the globe.

According to the American Cancer Society (ACS), in year 2014, more than 14 million people were suffering from cancer in U.S. Further, about 1,658,370 new cases of cancer are expected to be diagnosed in 2015. According to the World Health Organization (WHO) estimate, around 8.2 million patients died of cancer in 2012 and new cases are expected to rise by 70% over the next 2 decades. Moreover, in almost half of the cases, cancer is diagnosed at advanced stages, which reduces the chances of patient survival. Early identification/detection helps to take timely preventive measures, slow the progress of cancer and improve the chance of survival. Hence, there is an impending need for specific and sensitive biomarkers which would help in early diagnosis of cancer.

Request a Brochure of This Report, here: http://www.intenseresearch.com/market-analysis/world-cancer-biomarkers-market-opportunities-and-forecasts-2014.html#request-sample

The predominant factors driving the global cancer biomarkers market, are higher incidences of cancer and growing ageing population. The market would also gain prominence due to increasing cancer awareness, sedentary lifestyle, use of tobacco, smoking and excessive alcohol consumption. Furthermore, increasing R&D investment, and large number of pipeline drugs will further drive the market. However, high cost of treatment and ambiguous reimbursement scenario are likely to restrict the market growth.

The global cancer biomarkers market is segmented on the basis of cancer type, end user and geography. On the basis of cancer marker type, the market is segmented into Breast biomarker, Colorectal biomarker, Gastric biomarker, Gastrointestinal Stromal Tumours (GIST) biomarker, Leukemia/Lymphoma biomarker, Lung biomarker, Melanoma biomarker and other cancer biomarker. The market, according to end users is segmented into Hospitals and Diagnostic Centers and Research institutions. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA.

Do Inquiry Before Purchasing Report: http://www.intenseresearch.com/market-analysis/world-cancer-biomarkers-market-opportunities-and-forecasts-2014.html#inquiry-for-buying

Collaboration and product launch are few of the key strategies adopted by leading industry players. For instance, in Aug 2014, FDA approved Cologuard, a non-invasive screening test for the detection of DNA and haemoglobin biomarkers associated with colorectal cancer. In July 2014, AstraZeneca and Roche entered into collaboration to develop a companion diagnostic test which will be used for the identification of epidermal growth factor receptor (EGFR) biomarker in non-small-cell lung cancer.The companies profiled in the report include, Abbott Laboratories, F. Hoffmann-La Roche, Quest Diagnostics Affymetrix, Inc., Qiagen N.V., Illumina, Inc, Genelex Corporation, Beckman Coulter, Inc., Myriad Genetics, Inc. and bioMrieux SA.